The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / How to Manage, Treat Anemia of Inflammation in Patients with Rheumatic Disease

How to Manage, Treat Anemia of Inflammation in Patients with Rheumatic Disease

December 17, 2017 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Dr. Weiss explains, “Primarily, we treat the underlying disease. Successful response often results in resolution of anemia if the underlying anemia is anemia of chronic disease.” Patients may need a new or added agent to bring their disease under control or a higher dose of an existing treatment.

You Might Also Like
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
  • Plasma Complement Activation in Rheumatic Diseases May Accelerate Coronary Artery Disease
  • Pediatric Rheumatology Research Highlights Successful Approaches to Manage Juvenile Rheumatic Diseases
Explore This Issue
December 2017
Also By This Author
  • Granulomatosis with Polyangiitis Rates & Outcomes

Because of their mechanism, certain types of treatment may provide particular benefit in treating anemia of inflammation. Studies of TNF-α-blocking drugs have shown specific improvements, as have IL-6-blocking drugs such as tocilizumab. “These drugs act mainly by treating the underlying disease and reducing the inflammatory stimulus (via IL-6), which leads to the production of the master regulator of iron homeostasis, hepcidin,” explains Dr. Weiss. He notes that at this point the data do not support the use of one of these agents over any other.12,13

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

However, anemia may persist in some patients who do receive adequate treatment. Dr. Weiss explains, “It appears that a considerable number of patients with rheumatic diseases suffer from a combination of inflammatory anemia in association with true iron deficiency or vitamin deficiencies, which does not normalize after successful treatment of the rheumatic disease.” Because of this, he urges clinicians to gain a solid diagnostic understanding of the anemia and its underlying pathology.

It’s not clear in what specific situations iron, transfusions or erythropoietin-stimulating agents should be used. Clinicians may need to vary their therapeutic approach based on the underlying chronic condition, comorbidities & the specific needs of the individual patient.

Iron Therapy

Dr. Weiss emphasizes that the true cause of an iron deficiency must be evaluated. Any underlying iron deficiency should be treated with iron supplementation either orally or intravenously. Oral iron absorption can be limited in some patients with anemia of inflammation due to the inhibition of iron transfer from enterocytes to the circulation.1

Dr. Weiss notes, “If ferritin is low, then both options are feasible, because minute amounts of iron are absorbed under these circumstances, even when inflammation is present (as for example shown in patients with inflammatory bowel disease). Intravenous iron appears to be more appropriate in patients with normal ferritin and more inflammation; however, we are lacking pharmacokinetics and efficacy data of intravenous iron in this setting.”

Iron administration can also be used as a type of diagnostic measure in and of itself in differentiating anemia of inflammation from iron-deficiency anemia. “You can give supplemental iron and check their reticulocyte count about a week to 10 days later,” notes Dr. Koury. “If you see the retic count go up sharply, that would indicate a significant component of iron deficiency.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: Conditions Tagged With: anemia, Cause, Clinical, Diagnosis, inflammation, kidney, macrocytic anemia, Management, outcome, pathophysiology, patient care, Rheumatic Disease, rheumatologist, rheumatology, systemic inflammatory syndrome, Test, Treatment, vitamin deficiencyIssue: December 2017

You Might Also Like:
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
  • Plasma Complement Activation in Rheumatic Diseases May Accelerate Coronary Artery Disease
  • Pediatric Rheumatology Research Highlights Successful Approaches to Manage Juvenile Rheumatic Diseases
  • Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.